HLA-B12, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-HLA-B12, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | HLA-B12, Human |
| Clone | REA138 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | APC-Vio 770 conjugate |
| Size | 100 tests in 1 mL |
| Concentration | 1:11 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | HLA-B12 Antibody, anti-human, APC-Vio® 770, REAfinity™. Clone REA138 recognizes HLA B12, a class I human leukocyte antigen (HLA). Expressed on the surface of most nucleated cells, class I molecules are heterodimeric molecules and consist of a type I integral membrane α heavy chain and soluble β2 microglobulin protein. The extracellular region of the heavy chain further consists of three domains, of which one comprises the peptide binding groove. Antigens binding to class I molecules are 8-10 amino acids long and play an important role in recognition of the virus infected and malignant cells by cytotoxic T lymphocytes (CTLs). In addition, class I molecules interact with NK cell receptors to modulate the activity of NK cells. | Additional information: Clone REA138 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | HLA-B, AS, SPDA1 |
| Gene, Accession # | Gene ID: 3106 |
| Catalog # | 130-099-858 |
| Price | $360 |
| Order / More Info | HLA-B12, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Hewitt, E. W. et al. (2003) The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110 (2): 163-169. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies